|
Feds Not Addressing Drugs in Water
By MARTHA MENDOZA – 3 days ago
WASHINGTON (AP) — A White House task force that was supposed to devise
a federal plan to research the issue of pharmaceuticals in drinking
water has missed its deadline and failed to produce mandated reports
and recommendations for coordination among numerous federal agencies,
according to documents obtained by The Associated Press.
More than 70 pages of the task force's documents, including e-mails
and weekly reports, were released under the Freedom of Information Act
as a Senate subcommittee prepares to convene a hearing Tuesday prompted
by an AP investigation about trace concentrations of drugs in America's
drinking water.
The working group on pharmaceuticals in the environment was formed
two years ago through the White House Office of Science and Technology
Policy. The panel has met several times for briefings and is aware of
public concern about pharmaceuticals in water supplies, according to
the documents.
In a weekly report dated March 24, 2006, then-task force
coordinator Kevin Geiss, wrote: "There has been considerable
congressional interest in this topic."
But it is impossible to track any possible progress by the group
because the White House has classified task force agendas and minutes
as internal documents, and therefore cannot be released, said
spokeswoman Kristin Scuderi. The group's annual report is in draft form
and therefore also cannot be released at this time, she added.
While providing some documents to the AP, Rachael Leonard, a White
House deputy general counsel, said "10 inches worth of documents" were
not being released.
The group's deadline to produce a national research strategy came
and went in December. Scuderi said the task force needs extra time to
"serve as an internal federal vehicle to further enhance interagency
collaboration."
The group includes representatives from nine federal agencies
including the Environmental Protection Agency, Agriculture Department
and the Food and Drug Administration.
The lack of public disclosure and failure of federal agencies to
act on the pharmaceutical issue is expected to be a focus at Tuesday's
hearing before a subcommittee of the Senate Committee on Environment
and Public Works. Among others, officials from the EPA and U.S.
Geological Survey are scheduled to testify.
The hearing could produce a showdown between committee members and EPA officials.
Sen. Barbara Boxer, D-Calif., who heads the committee, and Sen.
Frank Lautenberg, D-N.J., chairman of the Transportation, Safety,
Infrastructure Security and Water Quality Subcommittee, wrote to EPA
Administrator Stephen Johnson on March 18 asking what the agency plans
to do to address concerns about pharmaceuticals in water. The EPA had
not responded, a Senate staff member said Friday.
The hearing was prompted by a five-month-long inquiry by the AP
National Investigative Team that disclosed the presence of trace
concentrations of pharmaceuticals in the drinking water of at least 41
million Americans.
The AP found that while water is screened for drugs by some
suppliers, they usually don't tell their customers of results showing
the presence of medications including antibiotics, anti-convulsants,
mood stabilizers and sex hormones.
The series revealed how drugs — mostly the residue of medications
taken by people, excreted and flushed down the toilet — have gotten
into the water supplies of at least 24 major metropolitan areas, from
Southern California to Northern New Jersey. The stories also detail the
growing concerns among scientists that this pollution has adversely
affected wildlife, and may be threatening human health.
EPA officials responded with concern, pledging to organize
additional research and by saying people should be informed if drugs
are detected in their water supplies.
But Kyla Bennett, a lawyer and former EPA biologist, said the EPA "is moving with all deliberate delay."
Bennett, who directs the New England branch of Public Employees for
Environmental Responsibility, said Congress first ordered the EPA to
address the issue 12 years ago.
"When it should be pressing forward, EPA is spinning in place, as if it has overdosed on pharmaceuticals," she said.
Others say funding has been pulled and priorities shifted.
"The EPA has missed the boat in really addressing the serious
consequences of pharmaceutical disposal," said Anna Gilmore-Hall,
executive director of Healthcare Without Harm.
Hall's nonprofit now runs what was the EPA's Hospitals for a
Healthy Environment stewardship program, designed to reduce mercury use
and improve the environmental footprint of the health care industry.
The EPA cut the $200,000-per-year program in 2003 after five years,
despite widespread interest and involvement from hospitals, declining
to even sit on the nonprofit's board.
Clean Water Action's New Jersey campaign Director David Pringle,
slated to testify at the hearing, said he plans to tell the senators
that "while it's not time to panic, it's a time of concern and we need
to take action."
Pringle said existing regulations are not being used and that
federal officials have known for years there are problems. "They've
clearly been dragging their feet," he said.
Local hearings and public meetings have already been held in
various cities including New York. The Philadelphia City Council has a
hearing prompted by the AP series scheduled for Monday.
The AP National Investigative Team can be reached at investigate (at) ap.org
|